Berkeley UC
From 2007.igem.org
(Difference between revisions)
| Line 10: | Line 10: | ||
</tr> | </tr> | ||
</table> | </table> | ||
| - | <img src="https://static.igem.org/mediawiki/2007/ | + | <img src="https://static.igem.org/mediawiki/2007/d/da/BerkiGEM2007-Bactoblood_text.jpg" border="0" id="Bactoblood_Header_Text_Img"> |
<p>The necessity of inexpensive, disease-free, and universally compatible blood substitutes is undisputed. There are currently no blood substitutes approved for use in the US or the UK, and whole blood is almost always in short supply. Developing countries have the greatest need for blood transfusions, yet many lack the necessary donation and storage infrastructure and the required pool of healthy donors. To address this problem, we are developing a cost-effective red blood cell substitute constructed from engineered <i>E. coli</i> bacteria. Our system includes the ability to transport oxygen, safely exist in the bloodstream without inducing sepsis, and be stored for prolonged periods in a freeze-dried state.<br /><br /></p> | <p>The necessity of inexpensive, disease-free, and universally compatible blood substitutes is undisputed. There are currently no blood substitutes approved for use in the US or the UK, and whole blood is almost always in short supply. Developing countries have the greatest need for blood transfusions, yet many lack the necessary donation and storage infrastructure and the required pool of healthy donors. To address this problem, we are developing a cost-effective red blood cell substitute constructed from engineered <i>E. coli</i> bacteria. Our system includes the ability to transport oxygen, safely exist in the bloodstream without inducing sepsis, and be stored for prolonged periods in a freeze-dried state.<br /><br /></p> | ||
<p><b><i>Support for Berkeley iGEM 2007 was generously provided by | <p><b><i>Support for Berkeley iGEM 2007 was generously provided by | ||
| Line 18: | Line 18: | ||
<p align="left"> | <p align="left"> | ||
| - | <table width="100%" id="table2" border="2" cellpadding="0" style="padding: 0px; width: 100%; color: navyblue; background-color: lightblue;"> | + | <table width="100%" id="table2" border="2" cellpadding="0" style="padding: 0px; width: 100%; color: navyblue; background-color: lightblue;" id="Main_Icons_Table"> |
<!--<tr> | <!--<tr> | ||
<td class="tdheadL"> </td> | <td class="tdheadL"> </td> | ||
| Line 79: | Line 79: | ||
<p><br /></p> | <p><br /></p> | ||
| - | <table width="100%" id="table3" border="2" style="padding: 0px; width: 100%; color: navyblue; background-color: #ffffaa;"> | + | |
| + | <table width="100%" id="table2" border="2" cellpadding="0" style="padding: 0px; width: 100%; color: navyblue; background-color: lightblue;" id="Secondary_Icons_Table"> | ||
| + | <!--<tr> | ||
| + | <td class="tdheadR" colspan="2"> | ||
| + | <h3>Other Stuff</h3></td> | ||
| + | </tr>--> | ||
| + | <tr> | ||
| + | <td class="tdsmallboxes"><a href="https://2007.igem.org/BerkiGEM2007Present6"><img border="0" src="https://static.igem.org/mediawiki/2007/6/67/Berk-Icon-Small-Placeholder.png" width="67" height="67"></a></td> | ||
| + | <td class="tddesc"><b><a href="https://2007.igem.org/BerkiGEM2007Present6">Human Practices</a></b><p><i>[ Blurb Here ]</i></td> | ||
| + | </tr> | ||
| + | <tr> | ||
| + | <td class="tdsmallboxes"><a href="https://2007.igem.org/Berkeley_Individual_Contributions"><img border="0" src="https://static.igem.org/mediawiki/2007/6/67/Berk-Icon-Small-Placeholder.png" width="67" height="67"></a></td> | ||
| + | <td class="tddesc"><b><a href="https://2007.igem.org/Berkeley_Individual_Contributions">Individual Contributions</a></b><p><i>The specific contributions made by each team member and advisor.</i></td> | ||
| + | </tr> | ||
| + | <tr> | ||
| + | <td class="tdsmallboxes"><a href="https://2007.igem.org/BerkiGEM2007_Resources"><img border="0" src="https://static.igem.org/mediawiki/2007/6/67/Berk-Icon-Small-Placeholder.png" width="67" height="67"></a></td> | ||
| + | <td class="tddesc"><b><a href="https://2007.igem.org/BerkiGEM2007_Resources">Team Resources</a></b><p><i>Organizational spreadsheets, useful tools and links.</i></td> | ||
| + | </tr> | ||
| + | <tr> | ||
| + | <td class="tdsmallboxes"><a href="https://2007.igem.org/BerkiGEM2007_Notebooks"><img border="0" src="https://static.igem.org/mediawiki/2007/6/67/Berk-Icon-Small-Placeholder.png" width="67" height="67"></a></td> | ||
| + | <td class="tddesc"><b><a href="https://2007.igem.org/BerkiGEM2007_Notebooks">Team Notebooks</a></b><p><i>The team members' daily logs of our research.</i></td> | ||
| + | </tr> | ||
| + | </table> | ||
| + | |||
| + | <p><br /></p> | ||
| + | |||
| + | <table width="100%" id="table3" border="2" style="padding: 0px; width: 100%; color: navyblue; background-color: #ffffaa;" id="Team_Members_Table"> | ||
<tr> | <tr> | ||
<td class="tdheadR" style="background-color: #ffffaa;"> | <td class="tdheadR" style="background-color: #ffffaa;"> | ||
| Line 85: | Line 111: | ||
</tr> | </tr> | ||
<tr> | <tr> | ||
| - | <td class="tddesc | + | <td class="tddesc"><b>Advisors</b><br /> |
| - | + | ||
<a href="/igem07/index.php/John_Dueber" title="John Dueber"> | <a href="/igem07/index.php/John_Dueber" title="John Dueber"> | ||
John Dueber</a> <font face="Arial">•</font> | John Dueber</a> <font face="Arial">•</font> | ||
| Line 94: | Line 119: | ||
Adam Arkin</a> <font face="Arial">•</font> | Adam Arkin</a> <font face="Arial">•</font> | ||
<a href="https://keaslinglab.lbl.gov/wiki/index.php/Main_Page" title="https://keaslinglab.lbl.gov/wiki/index.php/Main Page" rel="nofollow"> | <a href="https://keaslinglab.lbl.gov/wiki/index.php/Main_Page" title="https://keaslinglab.lbl.gov/wiki/index.php/Main Page" rel="nofollow"> | ||
| - | Jay Keasling</a><br / | + | Jay Keasling</a><br /> |
<p><b>Teaching Assistants</b><br /> | <p><b>Teaching Assistants</b><br /> | ||
<a href="/igem07/index.php/Farnaz_Nowroozi" title="Farnaz Nowroozi"> | <a href="/igem07/index.php/Farnaz_Nowroozi" title="Farnaz Nowroozi"> | ||
| Line 133: | Line 158: | ||
</tr> | </tr> | ||
</table> | </table> | ||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
</html> | </html> | ||
Revision as of 04:07, 24 October 2007
The necessity of inexpensive, disease-free, and universally compatible blood substitutes is undisputed. There are currently no blood substitutes approved for use in the US or the UK, and whole blood is almost always in short supply. Developing countries have the greatest need for blood transfusions, yet many lack the necessary donation and storage infrastructure and the required pool of healthy donors. To address this problem, we are developing a cost-effective red blood cell substitute constructed from engineered E. coli bacteria. Our system includes the ability to transport oxygen, safely exist in the bloodstream without inducing sepsis, and be stored for prolonged periods in a freeze-dried state.
Support for Berkeley iGEM 2007 was generously provided by SynBERC and The Camille and Henry Dreyfus Foundation, Inc.
The System's Components |
|
 |
Oxygen Transport Our system is designed to produce Hemoglobin, Heme, and the necessary chaperones and detoxifying agents to promote the transport of oxygen throughout the bloodstream. We also investigated alternates to hemoglobin and other strategies for its production. |
 |
The Chassis Our bacterial chassis has been heavily modified to remove its sepsis-inducing toxicity, immunogenic factors, and ability to grow within the bloodstream, as well as promote its ability to last longer in the bloodstream by masking it from the immune system. |
 |
The Controller The Controller is an integrated genetic circuit comprised of two plasmids that allows stable maintenance of the system's various operons on a large single-copy plasmid in a dormant state. Upon induction, the copy number of the operons and their transcription increase 100-fold resulting in a dramatic increase in protein expression. |
 |
Genetic Self-Destruct To prevent chance of infection or unwanted proliferation after hemoglobin production, we have engineered a genetic self-destruct mechanism whereby when induced, the bacterial cell will express a genetic material-degrading toxin which kills the cell, but leaves it physically intact. |
 |
Freeze Drying To enable preservation of our bacteria for long time periods, we are including the ability to produce the compounds hydroxyectoine and trehalose that will enable our bacteria to survive freeze-drying intact. This will dramatically increase shelf-life and decrease transport costs. |
 |
Human Practices [ Blurb Here ] |
|
Individual Contributions The specific contributions made by each team member and advisor. |
|
Team Resources Organizational spreadsheets, useful tools and links. |
|
Team Notebooks The team members' daily logs of our research. |
Team Members |
| Advisors John Dueber • Christopher Anderson • Adam Arkin • Jay Keasling Teaching Assistants Support Undergraduate Researchers High School Students |
